AU2001264736B2 - Gabapentin analogues for sleep disorders - Google Patents

Gabapentin analogues for sleep disorders Download PDF

Info

Publication number
AU2001264736B2
AU2001264736B2 AU2001264736A AU2001264736A AU2001264736B2 AU 2001264736 B2 AU2001264736 B2 AU 2001264736B2 AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 B2 AU2001264736 B2 AU 2001264736B2
Authority
AU
Australia
Prior art keywords
acetic acid
aminomethyl
cyclopentyl
cyclobutyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001264736A
Other languages
English (en)
Other versions
AU2001264736A1 (en
Inventor
Justin Stephen Bryans
Leonard Theodore Meltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001264736A1 publication Critical patent/AU2001264736A1/en
Application granted granted Critical
Publication of AU2001264736B2 publication Critical patent/AU2001264736B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001264736A 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders Ceased AU2001264736B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21417100P 2000-06-26 2000-06-26
US60/214,171 2000-06-26
PCT/US2001/016343 WO2002000209A2 (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Publications (2)

Publication Number Publication Date
AU2001264736A1 AU2001264736A1 (en) 2002-03-28
AU2001264736B2 true AU2001264736B2 (en) 2006-04-27

Family

ID=22798045

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001264736A Ceased AU2001264736B2 (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders
AU6473601A Pending AU6473601A (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6473601A Pending AU6473601A (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Country Status (23)

Country Link
US (1) US7141606B2 (enExample)
EP (1) EP1296671B1 (enExample)
JP (1) JP3909842B2 (enExample)
KR (1) KR100785182B1 (enExample)
CN (1) CN1279900C (enExample)
AT (1) ATE390133T1 (enExample)
AU (2) AU2001264736B2 (enExample)
BR (1) BR0111913A (enExample)
CA (1) CA2414008C (enExample)
CZ (1) CZ20024110A3 (enExample)
DE (1) DE60133389T2 (enExample)
DK (1) DK1296671T3 (enExample)
ES (1) ES2300332T3 (enExample)
HU (1) HUP0300833A3 (enExample)
IL (2) IL152770A0 (enExample)
MX (1) MXPA02010668A (enExample)
NZ (1) NZ522480A (enExample)
PL (1) PL359872A1 (enExample)
PT (1) PT1296671E (enExample)
SK (1) SK17922002A3 (enExample)
TW (1) TWI298020B (enExample)
WO (1) WO2002000209A2 (enExample)
ZA (1) ZA200209418B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
EP1622603A4 (en) * 2003-03-25 2010-03-24 Kiel Lab Inc GABAPENTINIC PHENOLIC ACID SALTS IN SOLID DOSAGE FORMS AND METHODS OF USE
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
JP2005325070A (ja) * 2004-05-14 2005-11-24 Ss Pharmaceut Co Ltd 睡眠改善剤
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
AU2006262502A1 (en) 2005-06-23 2007-01-04 Emory Univerisity Imaging agents
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CA2640402C (en) * 2006-03-06 2012-01-03 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
SG10201912843YA (en) * 2016-05-26 2020-02-27 Amino Up Chemical Co Ltd Sleep improving agent
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態
CN117776950B (zh) * 2022-09-20 2025-12-23 中科中山药物创新研究院 一种γ-氨基丁酸衍生物、药物组合物和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
EA001214B1 (ru) * 1996-03-14 2000-12-25 Варнер-Ламберт Компани Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
BR9911887A (pt) 1998-07-09 2001-03-27 Warner Lambert Co Método para o tratamento da insÈnia
JP2003525207A (ja) * 1999-06-02 2003-08-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用なアミノ複素環
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
BR0016201A (pt) * 1999-12-08 2002-08-13 Warner Lambert Co Método para a sìntese estereosseletiva de aminoácidos cìclicos
GB9930083D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 02/00209 *

Also Published As

Publication number Publication date
HUP0300833A3 (en) 2009-08-28
SK17922002A3 (sk) 2003-11-04
TWI298020B (en) 2008-06-21
IL152770A0 (en) 2003-06-24
CA2414008A1 (en) 2002-01-03
DK1296671T3 (da) 2008-06-16
CN1279900C (zh) 2006-10-18
DE60133389D1 (de) 2008-05-08
KR20030019455A (ko) 2003-03-06
CA2414008C (en) 2011-04-26
DE60133389T2 (de) 2008-06-26
ES2300332T3 (es) 2008-06-16
JP3909842B2 (ja) 2007-04-25
CZ20024110A3 (cs) 2003-10-15
NZ522480A (en) 2005-06-24
US7141606B2 (en) 2006-11-28
PL359872A1 (en) 2004-09-06
CN1436075A (zh) 2003-08-13
AU6473601A (en) 2002-01-08
ZA200209418B (en) 2005-03-10
PT1296671E (pt) 2008-05-09
KR100785182B1 (ko) 2007-12-11
HUP0300833A2 (hu) 2003-08-28
EP1296671A2 (en) 2003-04-02
JP2004501189A (ja) 2004-01-15
WO2002000209A3 (en) 2003-01-16
HK1056681A1 (en) 2004-02-27
US20030212133A1 (en) 2003-11-13
IL152770A (en) 2009-12-24
EP1296671B1 (en) 2008-03-26
ATE390133T1 (de) 2008-04-15
MXPA02010668A (es) 2003-03-10
WO2002000209A2 (en) 2002-01-03
BR0111913A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
CA2414008C (en) Gabapentin analogues for sleep disorders
AU2001264736A1 (en) Gabapentin analogues for sleep disorders
US4877620A (en) Ibuprofen-containing medicament
ES2244103T3 (es) Remedio para enfermedades neurodegenerativas.
EP0306060B1 (en) Pharmaceutical products providing enhanced analgesia
CA2151724C (en) Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac
RU2005104418A (ru) Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP3192141B2 (ja) 抗うつ剤
AU765038B2 (en) Method for the treatment of insomnia
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
US5519057A (en) Ibuprofen-containing medicament
US20060052455A1 (en) Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
US5948806A (en) Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan)
US3932652A (en) Antidepressant compositions
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
US4663345A (en) Etodolac for treatment of gout
US4716177A (en) Tolrestat for inhibition of weight gain
EP1124547A1 (en) Pharmaceutical combination of mildronate and enalapril
RU2174836C1 (ru) Фармацевтическая композиция, обладающая анальгезирующим действием
US3772440A (en) Method for the treatment of parkinsonism and depression
AU2007222112A1 (en) Alpha-2-delta ligands for non-restorative sleep
JP2003277258A (ja) 片頭痛治療剤
MXPA00011647A (en) The treatment of renal colic with gaba analogs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired